The role of consolidating radiation therapy (RT) is very controversial in Hodgkin lymphoma (HL),especially in adolescents and young adults (AYA) HL.The key problem is how to achieve better therapeutic effect but bear less toxicities in chemotherapy and radiotherapy,which will be hopefully solved by clinical trials adopting interim positron emission tomography (iPET) scanning to guide therapy for HL.The new technologies including whole genome amplification (WGA),high-throughput gene sequencing (NGS) assay and genome-wide association study (GWAS) further illustrate abnormal signaling pathways in HL,such as NF-κB,JAK/STAT and PI3K pathway,which may provide new therapeutic targets for the disease.

TWO average expense control(TAEC) is the method that the hospital want to control the increasing breadth of medicine expense by limiting the total expense which include both clinic expense and hospitalize expense.TAEC will fake great help to improve the relationship of docfor and patient and to promote the hospital work.But the method of TAEC will also to be optimize further.

Objective To evaluate the clinical effects of the interlocking intramedullary nails in treatment of the floating knee. Methods Internal fixation with the interlocking nail in unilateral femur and tibia was performed on 6 patients with the floating knee, and the treatments of complications were analyzed and summarized. Results After operation the 6 patients were followed up and their X ray films were reviewed after 3, 6, and 12 months respectively. Fractures in unilateral femur and tibia healed at once in 4 patients, the union of one femur fracture delayed in one case and the union of tibia fracture delayed in one case. The knee joint could flex to 80～90 degrees in 5 of the 6 patients, and the other one could flex to 60 degrees. No shortening of the limb occurred in all the patients who healed after 6～18 months. Conclusion As the “floating knee”is a kind of high energy injury, often complicated with injury of important organs, the complication should be treated while the internal fixation be conducted as soon as possible. The interlocking intramedullary nail is a good device with which the function of the limb can recover fast with the postoperative dysfunction of the knee and ankle joints greatly reduced.

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma with highly heterogeneous clinical course. How to recognize patients with high risk is coming into the focus of the 57th American Society of Hematology (ASH) annual meeting. The International Prognostic Index (IPI) score as a classic prognostic system is challenged by variety of new prognosis systems. The tumor microenvironment plays an important role in progression of lymphoma, and its prognostic value draw much more attention. The value of PET-CT for prognosis of DLBCL has also been affirmed in this meeting.

Bone marrow-derived mesenchymal stem cells (MSCs) are capable of migrating and homing to brain tumors in vivo and therefore is a promising targeted-delivery vehicle in cancer gene therapy. MSCs are transfected or transducted with the therapeutic genes and achieve stable expression in vitro, then are delivered to the host to exert their therapeutic effects. The Ex Vivo gene transfer of MSCs has been studied in several types of tumors including gliomas, and results were postive. The safety of MSC-based gene delivery remains to be controversial. The interactions between MSCs and host tumor cells need to be investigated.

Waldenstrom macroglobulinemia (WM) is a malignant B-cell lymphoproliferative disorder, which still remains incurable. Reports on the latest research progress of WM were presented in the 58th American Society of Hematology (ASH) Annual Meeting, covering the theoretical and clinical researches of this disease. In basic research, mechanism of ibrutinib resistance has been further explored. The application of modern technologies, such as next-generation sequencing, has promoted the pathogenesis and prognosis of WM. In clinical research, retrospective analyses of traditional treatment provide new theoretical foundation in the choice of regimen, while clinical trials on new drugs including BGB-3111 and oprozomib may improve the therapy. The research advances in WM will be summarized in this paper.

Hodgkin lymphoma (HL) is a highly curable malignancy for most patients. Frontline treatment is generally ABVD alone or combination with other chemotherapy regimens or radiation. However, the treatment of relapsed refractory HL (RR HL) remains a major challenge for clinicians. High dose chemotherapy followed by autologous stem cell transplantation is the preferred treatment for chemoresistant patients. In addition, the combination of brentuximab vedotin (BV) with programmed cell death receptor 1 monoclonal antibody nivolumab, BV combined with ICE (ifosfamide, carboplatin, etoposide), panobinotast in combination with ICE and many other new drugs are in clinical trials and research. The latest progress in treatment of HL is reported in depth in the 58th American Society of Hematology Annual Meeting.

Lenalidomide is an oral immunomodulator with multiple functions including immune regulation, anti-tumor, and regulation of tumor microenvironment. Since the United States Food and Drug Administration (FDA) approved lenalidomide for the treatment of mantle cell lymphoma, recent studies have indicated that lenalidomide monotherapy or lenalidomide combinations in other types of lymphoma also has broad prospects. The treatment progress of lenalidomide in lymphoma will be summarized in this paper based on the new reports in the 57th American Society of Hematology (ASH) annual meeting.

With the recent success of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, and the phosphoinositide-3-kinase (PI3K) inhibitor idelalisib in the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL), a number of new agents targeting the B cell receptor (BCR) pathway are in clinical development. In the 57th American Society of Hematology (ASH) annual meeting, great interests are still focused on these two drugs, either monotherapy or combination in the treatment of CLL. On the other hand, SYK inhibitors, new BTK and PI3K antagonists are also coming to the forefront, casting a new light on the treatment of ibrutinib/idelalisb-resistant patients. The progresses of BCR pathway inhibitors in CLL will be summarized in this paper based on the reports in the 57th ASH annual meeting.

Chronic lymphocytic leukemia (CLL) is a kind of malignant B-cell chronic lymphoproliferative disorder with highly heterogeneous clinical courses. Due to the recent advances in immunology, cellular genetics and molecular biology, several prognostic markers based on genetic, phenotypic, and molecular biology characteristics of CLL cells have emerged in the past decade. This article reviews the reports from the 57th American Society of Hematology (ASH) annual meeting on the progress of the prognosis of CLL.